APP and sarcopenia: Although further studies are necessary to dissect the molecular factors linking APP processing to cholinergic loss and possibly muscle dysfunction (e.g., sarcopenia), our data raise the interesting possibility that targeting the cholinergic system could be useful for the treatment of sarcopenia and other muscle pathologies that accompany AD clinical progression.